AdvanSix Announces First Quarter 2018 Financial Results
Sales of
Cash Flow from Operations of
Earnings Per Share of
Board of Directors authorizes
First Quarter 2018 Highlights
- Sales down 5% versus prior year, including 8% volume decline as a result of the 1Q18 weather-related event, 2% favorable impact of market-based pricing, and 1% higher raw material pass-through pricing
- 1Q18 weather-related event resulted in an approximately
$30 million unfavorable impact to pre-tax income, as previously disclosed, including the unfavorable impact of fixed cost absorption, maintenance expense and incremental raw material costs, in addition to lost sales - Net Income of
$11.6 million , a decrease of$15.7 million versus the prior year - EBITDA of
$30.8 million , a decrease of$26.3 million versus the prior year - Cash Flow from Operations of
$44.1 million , an increase of$12.9 million versus the prior year - Free Cash Flow of
$13.4 million , an increase of$15.4 million versus the prior year
“This quarter's results again demonstrate our ability to navigate a dynamic environment and highlight the resiliency of our organization. We successfully managed weather-related temporary production challenges, maintained our focus on safe operations and generated higher free cash flow. We also captured the benefit of improved market-based pricing this quarter, supported by a continued favorable supply and demand environment for our product lines overall,” said
Summary first quarter 2018 financial results for the Company are included below:
|
First Quarter 2018 Results |
||||
| ($ in Thousands, Except Earnings Per Share) | 1Q 2018 | 1Q 2017 | ||
| Sales | |
|
||
| Net Income | 11,593 | 27,293 | ||
| Earnings Per Share (Diluted) | |
|
||
| EBITDA (1) | 30,790 | 57,076 | ||
| EBITDA Margin % (1) | 8.6% | 15.2% | ||
| Cash Flow from Operations | 44,067 | 31,206 | ||
| Free Cash Flow (1)(2) | 13,354 | (2,008) |
|
(1) |
See “Non-GAAP Measures” included in this press release for non-GAAP reconciliations |
|
|
(2) |
Net cash provided by operating activities less capital expenditures |
|
Sales volume in the quarter decreased 8% versus the prior year due to the unfavorable impact from the 1Q18 weather-related event. Pricing overall increased 3% versus the prior year, including a 1% favorable impact from raw material pass-through pricing driven by increases in benzene and propylene (inputs to cumene which is a key feedstock to our products) costs. Market-based pricing was favorable by 2% compared to the prior year with improved industry supply and demand dynamics in our nylon and chemical intermediates product lines.
Sales by product line represented the following approximate percentage of our total sales:
| 1Q 2018 | 1Q 2017 | |||
| Nylon | 28% | 29% | ||
| Caprolactam | 18% | 21% | ||
| Ammonium Sulfate Fertilizers | 19% | 18% | ||
| Chemical Intermediates | 35% | 32% | ||
EBITDA of
Cash flow from operations of
Outlook
- Current favorable nylon industry conditions expected to continue; Late start to
North America planting season impacts timing of fertilizer application - Full year 2018 planned plant turnarounds expected to be consistent with historical levels in total (
$30 to$35 million pre-tax income impact) - Capital Expenditures expected to be
$110 to$120 million for the full year 2018, including$20 to$30 million incremental investment toward high-return growth and cost savings project pipeline - Board of Directors authorized the Company to repurchase up to
$75 million of its common stock as part of its capital deployment strategy
“We continue to position the Company for strong operational and financial performance for years to come. We are focused on delivering strong results for the remainder of 2018, while increasing our investment in high-return growth and cost savings projects for sustained long-term performance. Additionally, our first share repurchase authorization demonstrates confidence in our continued cash flow generation and our commitment to delivering value to our shareholders,” added Kane.
Conference Call Information
About
Forward Looking Statements
This release contains certain statements that may be deemed “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, that address activities, events or developments that our management intends, expects, projects, believes or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements may be identified by words like "expect," "anticipate," "estimate," “outlook”, "project," "strategy," "intend," "plan," "target," "goal," "may," "will," "should" and "believe" or other variations or similar terminology. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results or performance of the company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: general economic and financial conditions in the
Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures intended to supplement, not to act as substitutes for, comparable GAAP measures. Reconciliations of non-GAAP financial measures to GAAP financial measures are provided in this press release. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided. Non-GAAP measures in this press release may be calculated in a way that is not comparable to similarly-titled measures reported by other companies.
| |
||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| (Dollars in thousands, except share and per share amounts) | ||||||||
| |
|
|||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 29,352 | $ | 55,432 | ||||
| Accounts and other receivables – net | 162,910 | 196,003 | ||||||
| Inventories – net | 124,635 | 129,208 | ||||||
| Other current assets | 5,690 | 7,130 | ||||||
| Total current assets | 322,587 | 387,773 | ||||||
| Property, plant and equipment – net | 615,498 | 612,612 | ||||||
| |
15,005 | 15,005 | ||||||
| Other assets | 37,391 | 34,884 | ||||||
| Total assets | $ | 990,481 | $ | 1,050,274 | ||||
| LIABILITIES | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 195,699 | $ | 227,711 | ||||
| Accrued liabilities | 25,382 | 35,013 | ||||||
| Income taxes payable | 817 | 1 | ||||||
| Deferred income and customer advances | 17,126 | 17,194 | ||||||
| Line of credit – short-term | 37,600 | — | ||||||
| Current portion of long-term debt | — | 16,875 | ||||||
| Total current liabilities | 276,624 | 296,794 | ||||||
| Deferred income taxes | 94,017 | 92,276 | ||||||
| Line of credit – long-term | 192,400 | — | ||||||
| Long-term debt | — | 248,339 | ||||||
| Postretirement benefit obligations | 33,629 | 33,396 | ||||||
| Other liabilities | 3,983 | 3,144 | ||||||
| Total liabilities | 600,653 | 673,949 | ||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Common stock, par value 30,508,322 shares issued and 30,499,327 outstanding at 30,482,966 shares issued and outstanding at |
305 | 305 | ||||||
|
Preferred stock, par value |
— | — | ||||||
| |
— | — | ||||||
| Additional paid-in capital | 264,992 | 263,081 | ||||||
| Retained earnings | 133,168 | 121,985 | ||||||
| Accumulated other comprehensive loss | (8,637 | ) | (9,046 | ) | ||||
| Total stockholders' equity | 389,828 | 376,325 | ||||||
| Total liabilities and stockholders' equity | $ | 990,481 | $ | 1,050,274 | ||||
| |
||||||||
| Condensed Consolidated Statements of Operations | ||||||||
| (Unaudited) | ||||||||
| (Dollars in thousands, except share and per share amounts) | ||||||||
| Three Months Ended | ||||||||
| |
||||||||
| 2018 | 2017 | |||||||
| Sales | $ | 359,238 | $ | 376,704 | ||||
| Costs, expenses and other: | ||||||||
| Costs of goods sold | 321,320 | 313,896 | ||||||
| Selling, general and administrative expenses | 19,213 | 16,770 | ||||||
| Other non-operating expense (income), net | 3,546 | 1,797 | ||||||
| 344,079 | 332,463 | |||||||
| Income before taxes | 15,159 | 44,241 | ||||||
| Income taxes | 3,566 | 16,948 | ||||||
| Net income | $ | 11,593 | $ | 27,293 | ||||
| Earnings per common share | ||||||||
| Basic | $ | 0.38 | $ | 0.90 | ||||
| Diluted | $ | 0.37 | $ | 0.88 | ||||
| Weighted average common shares outstanding | ||||||||
| Basic | 30,488,601 | 30,482,966 | ||||||
| Diluted | 31,285,365 | 30,894,254 | ||||||
| |
||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (Unaudited) | ||||||||
| (Dollars in thousands) | ||||||||
| Three Months Ended |
||||||||
| 2018 | 2017 | |||||||
| Cash flows from operating activities: | ||||||||
| Net income | $ | 11,593 | $ | 27,293 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 12,542 | 11,296 | ||||||
| Loss on disposal of assets | 311 | 534 | ||||||
| Deferred income taxes | 1,741 | 11,706 | ||||||
| Stock based compensation | 2,281 | 1,684 | ||||||
| Accretion of deferred financing fees | 1,480 | 148 | ||||||
| Changes in assets and liabilities: | ||||||||
| Accounts and other receivables | 33,092 | (36,295 | ) | |||||
| Inventories | 4,573 | 16,941 | ||||||
| Accounts payable | (16,468 | ) | (176 | ) | ||||
| Income taxes payable | 816 | 5,152 | ||||||
| Accrued liabilities | (9,631 | ) | (2,823 | ) | ||||
| Deferred income and customer advances | (68 | ) | (5,860 | ) | ||||
| Other assets and liabilities | 1,805 | 1,606 | ||||||
| Net cash provided by operating activities | 44,067 | 31,206 | ||||||
| Cash flows from investing activities: | ||||||||
| Expenditures for property, plant and equipment | (30,713 | ) | (33,214 | ) | ||||
| Other investing activities | (1,002 | ) | (121 | ) | ||||
| Net cash used for investing activities | (31,715 | ) | (33,335 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Payment of long-term debt | (266,625 | ) | — | |||||
| Borrowings from line of credit | 246,000 | 167,500 | ||||||
| Payments of line of credit | (16,000 | ) | (167,500 | ) | ||||
| Payment of line of credit fees | (1,362 | ) | — | |||||
| Principal payments under capital lease | (75 | ) | (42 | ) | ||||
| Purchase of treasury shares | (370 | ) | — | |||||
| Net cash used for financing activities | (38,432 | ) | (42 | ) | ||||
| Net decrease in cash and cash equivalents | (26,080 | ) | (2,171 | ) | ||||
| Cash and cash equivalents at beginning of period | 55,432 | 14,199 | ||||||
| Cash and cash equivalents at the end of period | $ | 29,352 | $ | 12,028 | ||||
| Supplemental non-cash investing activities: | ||||||||
| Capital expenditures included in accounts payable | $ | 9,753 | $ | 14,295 | ||||
| |
||||||||
| Non-GAAP Measures | ||||||||
| (Dollars in thousands) | ||||||||
| Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow | ||||||||
| Three Months Ended | ||||||||
| |
||||||||
| 2018 | 2017 | |||||||
| Net cash provided by operating activities | $ | 44,067 | $ | 31,206 | ||||
| Expenditures for property, plant and equipment | (30,713 | ) | (33,214 | ) | ||||
| Free cash flow (1) | $ | 13,354 | $ | (2,008 | ) | |||
|
(1) |
Free cash flow is a non-GAAP measure and defined as Net cash provided by operating activities less Expenditures for property, plant and equipment |
|
The Company believes that this metric is useful to investors and management as a measure to evaluate our ability to generate cash flow from business operations and the impact that this cash flow has on our liquidity.
|
Reconciliation of Net Income to EBITDA |
||||||||
| Three Months Ended | ||||||||
| |
||||||||
| 2018 | 2017 | |||||||
| Net income | $ | 11,593 | $ | 27,293 | ||||
| Interest expense, net | 3,089 | 1,539 | ||||||
| Income taxes | 3,566 | 16,948 | ||||||
| Depreciation and amortization | 12,542 | 11,296 | ||||||
| EBITDA (2) | $ | 30,790 | $ | 57,076 | ||||
| Sales | $ | 359,238 | $ | 376,704 | ||||
| EBITDA margin (3) | 8.6% | 15.2% | ||||||
|
(2) |
EBITDA is a non-GAAP measure and defined as Net Income before Interest, Income Taxes, Depreciation and Amortization |
|
|
(3) |
EBITDA margin is defined as EBITDA divided by Sales |
|
The Company believes these non-GAAP financial measures provide meaningful supplemental information as they are used by the Company’s management to evaluate the Company’s operating performance, enhance a reader’s understanding of the financial performance of the Company, and facilitate a better comparison among fiscal periods and performance relative to its competitors, as these non-GAAP measures exclude items that are not considered core to the Company’s operations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180504005254/en/
Media
debra.lewis@advansix.com
or
Investors
adam.kressel@advansix.com
Source:
Utg Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities: (Apr. 23, 2018)
Quotidian Technical Highlights on Selected Insurance Stocks — Radian, Allstate, Hartford Financial Services, and Validus
Advisor News
- Addressing the longevity paradox
- Employers shift focus from retirement access to financial outcomes
- Helping widowed clients navigate their new financial reality
- Navigating client communication in a digital age
- Can your advisory firm survive without you?
More Advisor NewsAnnuity News
- Farm Bureau P&C insurers post first underwriting gain since 2021
- Legacy Marketing, Malibu Life launch two fixed indexed annuities
- Changing client priorities are reshaping annuity conversations
- Solen Software acquires annuity software provider Cooperative Technologies
- MassMutual Expands Lending Options With New Secured Credit Line
More Annuity NewsHealth/Employee Benefits News
- Reports Summarize Managed Care Study Results from Brown University (Litigating the No Surprises Act: How Legal Challenges Undermined Cost Containment and Reshaped Provider Payments): Managed Care
- Researchers from Geisinger Provide Details of New Studies and Findings in the Area of Managed Care and Specialty Pharmacy (Trends In Annual Medication Possession In Older Adults With Type 2 Diabetes): Drugs and Therapies – Managed Care and Specialty Pharmacy
- Job-Based Health Plan Costs Rise, With Little Relief in Sight
- Here’s what Gov. Moore and Dan Cox promised Marylanders with disabilities
- AmeriHealth Caritas to join Ohio Health Insurance Marketplace in 2027
More Health/Employee Benefits NewsLife Insurance News